SEARCH

SEARCH BY CITATION

References

  • 1
    Prandoni P, Polistena P, Bernardi E, Cogo A, Casara D, Verlato F, Angelini F, Simioni P, Signorini G, Benedetti L, Girolami A. Upper-extremity deep vein thrombosis: risk factors, diagnosis, and complications. Arch Intern Med 1997; 157: 5762.
  • 2
    Horne M, May D, Alexander H, Steinhaus E, Whitman E, Chang R, Doppman J. Venographic surveillance of tunneled venous access devices in adult oncology patients. Ann Surg Oncol 1995; 2: 1748.
  • 3
    Allen A, Magargell J, Brown D, Lynch F, Singh H, Singh Y, Waybill P. Venous thrombosis associated with the placement of peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11: 130914.
  • 4
    Lobo B, Valdean G, Broyles J, Reaves A, Shorr R. Risk of venous thromboembolism in hospitalized patients with peripherally inserted central catheters. J Hosp Med 2009; 4: 41722.
  • 5
    Hingorani A, Ascher E, Lorenson E, DePippo P, Salles-Cunha S, Scheinman M, Yorkovich W, Hanson J. Upper extremity deep venous thrombosis and its impact on morbidity and mortality rates in a hospital-based population. J Vasc Surg 1997; 26: 85360.
  • 6
    Savage K, Wells P, Schulz V, Goudie D, Morrow B, Cruickshank M, Kovacs M. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999; 82: 100810.
  • 7
    Prandoni P, Bernardi E, Marchiori A, Lensing A, Prins M, Villalta S, Bagatella P, Sartor D, Piccioli A, Simioni P, Pagnan A, Girolami A. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ 2004; 329: 4845.
  • 8
    Lee A, Levine M, Baker R, Bowden C, Kakkar A, Prins M, Rickles F, Julian J, Haley S, Kovacs M, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 14653.
  • 9
    Kearon C, Kahn S, Agnelli G, Goldhaber S, Raskob G, Comerota A. Antithrombotic therapy for venous thromboembolic disease. Chest 2008; 133: 464.
  • 10
    Karabay O, Yetkin U, Onol H. Upper extremity deep vein thrombosis: clinical and treatment characteristics. J Int Med Res 2004; 32: 42935.
  • 11
    Kovacs M, Kahn S, Rodger M, Anderson D, Andreou R, Mangel J, Morrow B, Clement A, Wells P. A pilot study of central venous catheter survival in cancer patients using low-molecular weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5: 16503.
  • 12
    Joffe H, Kucher N, Tapson V, Goldhaber S for the DVT FREE steering committee. Upper-extremity deep vein thrombosis. A prospective registry of 592 patients. Circulation 2004; 110: 160511.
  • 13
    Munoz F, Mismetti P, Poggio R, Valle R, Burron M, Guil M, Monreal M for the RIETE Investigators. Clinical outcome of patients with upper-extremity deep vein thrombosis. Results from the RIETE registry. Chest 2008; 133: 1438.